Phase 2 N=48 Pasireotide LAR in Severe Polycystic Liver Disease
Somatostatin Analogs · Polycystic Liver Disease · Autosomal Dominant Polycystic Kidney Disease
Primary: Change in Liver Volume — -3.36; 6.29 percentage of change — p=0.001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=40 IRB 14-009240, Does CEUS Positively Influence Selection of Biopsy Sites When Evaluating Transplant Kidneys?
Transplantation, Kidney
Primary: Abnormal Biopsy — 10; 7 Participants
Phase 2 N=89 ATG-GCSF in New Onset Type 1 Diabetes
Diabetes Mellitus, Type 1
Primary: Change in Area Under the Stimulated C-peptide Curve From Baseline to 12 Months. — 0.528; 0.646; 0.406 nmol/L
Phase 4 N=11 Assessment of Gait After Dysport Treatment
Equinovarus; Acquired
Primary: Self-Selected Velocity (SSV) — 0.41; .48; 0.48; 0.52 m/s
Phase 3 N=530 Docetaxel+Oxaliplatin+S-1 (DOS) Regimen as Neoadjuvant Chemotherapy in Advanced Gastric Cancer
Gastric Cancer
Primary: Percentage of Participants With 3-Year Progression-Free Survival (PFS), as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST)1.1 — 60.24; 66.82 percentage…
Early Phase 1 N=106 Treatment With Metformin and Combination of Metformin and Pioglitazone in Polycystic Ovarian Syndrome
Polycystic Ovarian Syndrome
Primary: Cytokines and Chemokines Measurements — 14.60; 14.12; 12.65; 11.12 pg/ml
Phase 2 N=165 Efficacy and Safety Study of GSK3772847 in Subjects With Moderately Severe Asthma
Asthma
Primary: Percentage of Participants With Loss of Asthma Control Over Weeks 0-16 — 81; 67 Percentage of participants
Phase 4 N=48 A Study to Investigate Food Occlusion Efficacy of a Denture Adhesive in Denture Wearers
Denture Retention
Primary: Food Occlusion Analysis of Combined Mass of Peanuts Under Combined Maxillary (Upper) and Mandibular (Lower) Dentures — 5.56; 29.13 Milligrams (mg) — p=<0.0001
Phase 3 N=973 Bioequivalence Study With Clinical Endpoint Comparing Brinzolamide 1% Ophthalmic Suspension to Azopt® 1% Ophthalmic Suspension In the Treatment of Chronic Open Angle Glaucoma or Ocular Hypertension in Both Eyes
Glaucoma
Primary: Mean Difference in Intraocular Pressure (IOP) of Both Eyes Between the Two Treatment Groups at Four Time Points — 19.35; 19.75; 18.53; 18.66 mmHg
Phase 4 N=87 A 3-year Multi-center Study to Describe Changes of OCT Parameters Under Treatment With Gilenya®
Relapsing Remitting Multiple Sclerosis RRMS
Primary: Change From Baseline to Month 36 in Average Retinal Nerve Fiber Layer Thickness (RNFLT) — -1.5 micrometer
Phase 1 N=28 A Double-Blind Single-Ascending Dose (SAD) and Multiple-Ascending Dose (MAD) Study to Investigate the Safety, Tolerability, and Pharmacokinetics of RO7049389 in Healthy Chinese Participants
Hepatitis B Virus
Primary: Percentage of Participants With Adverse Events — 16.7; 0; 30.0; 10.0 Percentage of Participants
Phase 3 N=704 Study of Efficacy and Safety of QAW039 When Added to Standard-of-care Asthma Therapy in Patients With Uncontrolled Asthma
Asthma
Primary: Change From Baseline in Pre-dose FEV1 — 0.126; 0.157 Liters — p=0.214
Phase 2 N=276 In Vivo Preoperative Skin Preparation Persistence Evaluation
Bacterial Recovery of Skin Flora Post-product Application
Primary: Measurement of Skin Flora Recovery Post-prep Application — 1.39; 1.15; 1.97; 1.82 log10 CFU/cm^2 — p=0.13
Phase 2 N=41 STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Idiopathic Pulmonary Fibrosis (IPF)
Primary: Number of Participants With Adverse Events (AEs) — 6; 5; 6; 4 Participants
Phase 1 N=22 Pharmacokinetics Study of MCI-186 in Subjects With Mild or Moderate Hepatic Impairment
Hepatic Impairment · Healthy
Primary: Cmax — 538.1; 533.4; 429 ng/mL